A two-step vaccination approach using DNA priming followed by a peptide boost generated the strongest anti-tumor immune responses and eliminated tumors in most treated mice.
Most mice tumor-freeDNA prime-peptide boost eliminated EL4 tumors expressing the neo-epitope model in the majority of treated animals
What the researchers found
The DNA prime-peptide boost immunization strategy elicited the strongest CD8+ T-cell responses compared to homologous DNA-only or peptide-only approaches. These T cells showed both effector and memory precursor phenotypes and formed circulating and skin-resident memory T cells.
In prophylactic settings, this regimen delayed B16F10 melanoma growth and rejected EL4 lymphoma cells expressing a self-antigen. Therapeutically, the DNA prime-peptide boost eliminated EL4 tumors expressing the neo-epitope model in most mice. When targeting two bona fide neoepitopes of the MC38 tumor model, the strategy elicited neoepitope-specific CD8+ T-cell responses and a marked therapeutic effect that could be enhanced by combining with anti-PD-1 antibody.
Why it matters
Personalized cancer vaccines targeting neoantigens are a promising frontier in immunotherapy, but finding the most effective vaccination strategy is critical. This study demonstrates that a heterologous DNA prime-peptide boost approach outperforms single-platform vaccines, offering a practical blueprint for designing more potent neoantigen-based cancer immunotherapies that could eventually translate to human clinical trials.
How the study worked
Researchers compared homologous (same vaccine type twice) and heterologous (DNA then peptide) immunization strategies in mouse models using a neoantigen model. They measured CD8+ T-cell responses, characterized T-cell phenotypes, and tested both prophylactic and therapeutic tumor settings using B16F10 melanoma, EL4 lymphoma, and MC38 tumor models in C57BL/6 mice.
What this study cannot tell us
This study was conducted entirely in mouse models, and results may not directly translate to humans. The neoantigen models used are simplified compared to the complex mutational landscape of real human tumors. Specific numerical data on tumor rejection rates and T-cell expansion levels were described qualitatively in the abstract rather than with precise statistics. Long-term durability of the immune response was not fully characterized.
How to read the evidence
This is a preclinical animal study using multiple well-established mouse tumor models. While it demonstrates strong proof-of-concept results across several cancer types and both prophylactic and therapeutic settings, it has not yet been tested in humans.
When this study was published
Published in 2026, this is a very recent study reflecting current advances in neoantigen vaccine design and heterologous immunization strategies.
The bigger picture
This research fits into the rapidly evolving field of personalized cancer immunotherapy, where scientists are trying to train each patient's immune system to recognize their tumor's unique mutations. The finding that combining two different vaccine platforms works better than using either alone could influence how neoantigen vaccines are designed for clinical trials, potentially improving outcomes for patients with various cancer types.
Questions still open
- How well will the DNA prime-peptide boost strategy perform in human clinical trials with naturally occurring tumor neoantigens?
- What is the optimal timing and dosing interval between the DNA prime and peptide boost for maximum immune response?
- Could this approach be effective against tumors with lower mutational burdens that produce fewer neoantigens?
Common questions
What is a DNA prime-peptide boost vaccination strategy?
Could this approach be used to treat cancer in humans?
Read the original research
DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 + T cell responses and therapeutic protection in mouse tumor models.
Oncoimmunology, 15(1), 2606497
Citation
Morgado-Cáceres, Pablo; Hofmann-Vega, Francisca; Figueroa, Diego; Saavedra-Almarza, Juan; Gálvez-Cancino, Felipe; Díaz, Ximena; Menares, Evelyn; Roa, Eduardo; Hidalgo, Sofia; Varas-Godoy, Manuel; Borgna, Vincenzo; Lladser, Alvaro. (2026). DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 + T cell responses and therapeutic protection in mouse tumor models.. Oncoimmunology, 15(1), 2606497. https://doi.org/10.1080/2162402X.2025.2606497